Abstracts tagged "T Cell"

Abstract Number: 1726 • ACR Convergence 2025
Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
Xingxing Zhu¹, yue Yu¹, Yangfen Li¹, Panwen wang², ying li², Chantal McCabe², shiju chen², Brenna Sharp², Amber Wolzen², Hannah Langenfeld¹, Andrew C. Hanson¹, Cynthia Crowson³, svetomir Markovic², John Davis¹, Haidong Dong², Uma Thanarajasingam¹ and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: The immunological basis of inflammatory arthritis (IA) immune related adverse event (irAE) following anti-PD-1/PD-L1 immune checkpoint inhibition (ICI) therapy is incompletely understood. The relationship…
Abstract Number: 0101 • ACR Convergence 2025
Enrichment of putative bacteria-reactive gut-derived IL-17+ tissue resident memory helper T cells in arthritic ankles in the SKG mouse model of spondyloarthritis
Benjamin Cai¹, Megan Soon², Zewen Kelvin Tuong², Mark Morrison², Anne-Sophie Bergot³ and Ranjeny Thomas⁴, ¹Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia, ²Frazer Institute, The University of Queensland, Brisbane, Australia, ³Frazer Institute, The University of Queensland, Woolloongabba, Queensland, Australia, ⁴Frazer Institute, University of Queensland, Brisbane, Queensland, Australia
Background/Purpose: In spondyloarthropathy (SpA), arthritis is often associated with gut inflammation. The strong genetic association with HLA-B27 implicates involvement of T cells, but how gut…
Abstract Number: 0920 • ACR Convergence 2025
Functional Characterization of NEMO-NDAS Causing Variants in Patients’ PBMCs and in Wildtype and Mutant U937 Cells
Elizabeth Morgan¹, Bin Lin², Sara alehashemi¹, Adriana de Jesus¹, Keith Kauffman³, Christopher Friend¹, Farzana Bhuyan¹, Kader Gedik¹, Kat Uss¹, Lauren Krausfeldt⁴, Jason Brenchley⁵, Zoran Gucev⁶, Kathryn Cook⁷, Vafa Mammadova⁸, Gulnara Nasrullayeva⁸, Mariana Correia Marques⁹, Abigail Bosk¹⁰, Brian Nolan¹¹, Scott Canna¹², Maude Tusseau¹³, Andrea Bohrer¹⁴, Katrin Mayer-Barber¹⁵, Timothy Moran¹⁶, Andrew Oler⁴, Daniel Barber³ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Diseases Section (TADS), Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, MD, ²NIH, Bethesda, MD, ³T-Lymphocyte Biology Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, MD, ⁴Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, NIAID, NIH, Bethesda, MD, ⁵Barrier Immunity Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, ⁶University Children's Hospital, Medical Faculty Skopje, Skopje, Macedonia, ⁷Akron Children’s Hospital, Akron, OH, ⁸Azerbaijan Medical University, Baku, Azerbaijan, ⁹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Children’s National Hospital, Washington DC, ¹¹Lurie Children’s Hospital, Chicago, ¹²Children's Hospital of Philadelphia, Philadelphia, PA, ¹³Hôpital Femme-Mère-Enfant, Bron, France, ¹⁴Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, MD, ¹⁵Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology (LCIM), Bethesda, MD, ¹⁶University of North Carolina School of Medicine, Chapel Hill, NC
Background/Purpose: NEMO-deleted 5 autoinflammatory syndrome (NEMO-NDAS) is an inflammatory disease caused by mosaic splice-site variants that lead to exon 5 skipping in IKBKG, encoding NEMO.…
Abstract Number: 0997 • ACR Convergence 2025
Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan 
Olivia Pryor¹, Catalina Burbano², Nathaniel Bagge², Rutuja Kulkarni², Heather F. Jones², Livio Dukaj², Shoshana M.K. Bloom², Jackson Lirette², Rachel Lent², Prachi Dhanania², Nicole A. Ladd², Ryan Kritzer², Hana Husic², Shobitha Jillella², Candace R. Perullo², Jinyu Zhu², Teagan J. Parsons², Ira Jain², Rakshika Balasubramaniyam², Kenneth L. Jahan², Vivin Karthik², Alexander Cristofaro¹, Chandan K. Pavuluri², Jenna LaBelle², Laurie Barefoot², Shrikanta Chattopadhyay², Kim M. Cirelli², Mollie M. Jurewicz², Andrew P. Ferretti² and Cagan Gurer², ¹TScan Therapeutics, Waltham, ²TScan Therapeutics, Waltham, MA
Background/Purpose: Selective modulation of autoimmune responses through antigen-specific therapies represents a promising direction for improving treatment specificity and safety. Genetic associations with HLA class II…
Abstract Number: 1789 • ACR Convergence 2025
Spatial Analysis of Advanced Osteoarthritis Synovial Tissue
jacob Dickman¹, Stephanie Ruzicka¹, Holub Meaghan², Jutras Brandon³, Adam Edelstein³ and Robert Lochhead⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Central Michigan University College of Medicine, Mount Pleasant, MI, ³Northwestern University, Chicago, IL, ⁴Medical College of Wisconsin, GERMANTOWN, WI
Background/Purpose: Osteoarthritis (OA) is a joint pathology involving joint cartilage destruction and synovial inflammation. Severe knee OA is often surgically treated with total knee arthroplasty…
Abstract Number: 0110 • ACR Convergence 2025
SKG Mice Develop CD4⁺ T Cell–Driven Psoriasis and Enable Study of Endogenous Antigen-Specific Responses
Yuka Nakao¹, Astha Patel¹, Bahram Razani², Steven yu¹, Steven Lazarevsky², Marlys Fassett² and Judith Ashouri¹, ¹University of California, San Francisco, San Francisco, CA, ²UCSF Department of Dermatology, San Francisco, CA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are chronic immune-mediated diseases affecting millions, yet early immunologic triggers remain poorly defined. Therapies targeting TNFα, IL-17, and…
Abstract Number: 0948 • ACR Convergence 2025
Presentation of Apoptotic Cell-Derived Autoantigens in Systemic Autoimmune Disease
Lance Peterson¹, Hannah KL De Cleene², Cheryl Lichti², David Bending³ and Kodi Ravichandran², ¹Rheumatology and Immunology, Pediatrics, Washington University School of Medicine, St. Louis, MO, ²Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, ³Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, United Kingdom
Background/Purpose: Systemic lupus erythematosus is a chronic, multisystem autoimmune disease characterized by the dysregulated clearance of dying cells, which results in the release of damage-associated…
Abstract Number: 1000 • ACR Convergence 2025
A Deep-Learning Based Approach Uncovers Novel Mediators of Micro-RNA Restraint of Type-2 Immunity
Shaan Sekhon¹, Robin Kageyama², Neil Sprenkle³, Hannah Happ², Eric Wigton², Heather Pua³ and Mark Ansel², ¹University of California, San Francisco, Berkeley, ²University of California, San Francisco, San Francisco, ³Vanderbilt University, Nashville
Background/Purpose: MicroRNAs, such as miR-24 and miR-27, co-expressed within the Mirc11 and Mirc22 clusters, orchestrate a regulatory network critical to Th2 cell differentiation and cytokine…
Abstract Number: 2140 • ACR Convergence 2025
Identification of immune phenotypes in systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD) using high parameter flow cytometry
Haeja Kessler¹, Noel Gibson¹, Alyssa Sproles², Celine Lages¹, Paul Dascani³, Sherry Thornton⁴ and Grant Schulert⁴, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cytek Biosciences, Pittsburgh, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a unique subtype of juvenile idiopathic arthritis with life threatening complications including macrophage activation syndrome and chronic lung…
Abstract Number: 0273 • ACR Convergence 2025
Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis
Synat Keam¹, Yuanteng Li², Yanshuo Chu¹, Jean Tayar³, Huifang Lu⁴, Michael Wu⁵, Sandeep Agarwal⁶, Nitin Jain⁷, Pavlos Msaouel¹, Adi Diab², Cara Haymaker¹, Linghua Wang¹, Roza Nurieva⁸ and Sang Kim⁹, ¹The University of Texas MD Anderson Cancer Center, houston, ²MD Anderson Cancer Center, Houston, TX, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴UT MD Anderson Cancer Center, Houston, TX, ⁵Baylor College of Medicine, Houston, ⁶Baylor College of Medicine, Houston, TX, ⁷The Universty of Texas MD Anderson Cancer Center, Houston, ⁸University of Texas MD Anderson, Houston, TX, ⁹Yale University, Branford, CT
Background/Purpose: Immune checkpoint inhibitor (ICI) therapy is associated with life- and/or organ-threatening immune-related adverse events, including inflammatory arthritis (ICI-IA). However, the mechanisms behind ICI-IA, especially…
Abstract Number: 0950 • ACR Convergence 2025
Ep300-Catalyzed Rad50 Lactylation Compromises Genomic Stability and Drives CD4+T cells Cell Senescence in SLE
mingyang zhang¹, huanzi dai², cun lan³ and mingyang sun³, ¹Daping Hospital, Army Medical University, chongqing, Chongqing, China (People's Republic), ²Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic), ³Daping Hospital, Army Medical University, chongqing, China (People's Republic)
Background/Purpose: Senescent CD4+ T cells are increasingly implicated in systemic lupus erythematosus (SLE) pathogenesis. While metabolic reprogramming in lupus T cells enhances glycolysis and lactate…
Abstract Number: 1001 • ACR Convergence 2025
LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
Hongyan Shang¹, Xiao Huang², Duqing Jiang¹, Jianming Sun², Yurong Qin², Guojin Wu², Chengze Ni¹, Jing Guan², Jordan Zhu³, Xiaoqiang Kang² and Hong Ling², ¹Nanjing Leads Biolabs Co., Ltd., nanjing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ³Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Programmed cell death protein 1 (PD-1) is expressed on activated T cells and serves as a key co-inhibitory checkpoint molecule in immune regulation. Aberrant…
Abstract Number: 2277 • ACR Convergence 2025
Immunophenotyping of peripheral blood mononuclear cells reveals potential cellular biomarkers of disease in rheumatoid arthritis
John Bui¹, Jason Dubovsky², Jennifer Abrams³, Sara Charmsaz⁴, Michelle Blake¹, Joshua Beilke⁴, Anne-Renee van der Vuurst de Vries¹, Joseph Arron⁵, Jonathan Graf⁶ and Jeffrey Bluestone⁷, ¹Sonoma Biotherapeutics, Seattle, WA, ²Sonoma Biotherapeutics, South San Francisco, ³Sonomabio, San Francisco, CA, ⁴Sonoma Biotherapeutics, Seattle, ⁵Sonoma Biotherapeutics, San Francisco, CA, ⁶UCSF, San Francisco, CA, ⁷Sonoma Biotherapeutics, South San Francisco, CA
Background/Purpose: Emerging cell-based therapies for rheumatoid arthritis (RA) target the underlying immunologic activity of disease. Objective biomarkers to-date are downstream sequelae of RA immunologic drivers.…
Abstract Number: 0471 • ACR Convergence 2025
An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 Anti-CD19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial
Fredrik Albach¹, Ioanna Minopoulou¹, Artur Wilhelm², Robert Biesen¹, Arnd Kleyer¹, Norman Drzeniek³, Edgar Wiebe⁴, Anja Fleischmann³, Dominic Borie⁵, Vincent Casteleyn³, Tobias Alexander³, Christian Furth⁶, Jan Zernicke³, Burkhard Muche⁷, Sandra Hermann⁴, Pfeil Alexander⁸, Veronika Scholz³, Elpida Phithak³, Olaf Penack⁹, Kamran Movassaghi⁹, Eva Vanessa Schrezenmeier¹⁰, Udo Schneider³, Antonia Busse¹¹, Georg Schett¹², Ulrich Keller¹¹, Lars Bullinger⁹, Gerhard Krönke¹³, Marie Luise Hütter-Krönke¹⁴ and David Simon¹⁵, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁵Kyverna Therapeutics, Emeryville, CA, ⁶Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, ⁷Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁸Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany, ⁹Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany, Berlin, ¹⁰Department of Nephrology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, ¹¹Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; German Cancer Consortium (DKTK) partner site Charité Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany, Berlin, ¹²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ¹⁴Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany, Berlin, ¹⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by autoreactive B cells that produce anti-citrullinated protein antibodies (ACPA), contributing to sustained synovial inflammation…
Abstract Number: 0979 • ACR Convergence 2025
IL-23 upregulates IFN-γ secretion in Th17.1, but not in Th17 or classical Th1 cells
Bennie van Heeswijk¹, Wida Razawy², Anne-Marie Mus-Otten³, Patrick Asmawidjaja², Pieter Leenen² and Erik Lubberts⁴, ¹Erasmus MC, University Medical Center Rotterdam, Hoofddorp, Netherlands, ²Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands, ³Erasmus medical center, Rotterdam, Netherlands, ⁴Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: Interleukin-23 (IL-23) is a key cytokine in the pathogenesis of psoriatic diseases, as demonstrated by the clinical success of IL-23-targeted therapies. Monocytes are a…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].